Free Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • Europe Our alerts service is now closed until 7th January ...
  • Czech Republic Law reform to decriminalise adult use of cannabis passes first reading ...
  • France Concern about disruption in medical cannabis patients’ treatment ...
  • United States Resolution introduced that extends 2018 Farm Bill another year ...
  • Denmark Danish Medicines Agency approves medical cannabis oil product ...
  • Ohio - United States Bill to ban sale of intoxicating hemp products unlikely to move forward ...
  • Europe European Council adopts regulation to reduce and recycle packaging ...
  • Germany Two Berlin districts to start recreational cannabis sales ...
  • Nebraska - United States Two cannabis measures signed into law ...
  • Brazil AGU requests extension on deadline for cannabis regulations ...
  • Switzerland Bern recreational cannabis project extended ...
  • Japan Law in force today criminalises recreational and legalises medical cannabis ...
View all
News analysis

CBD prescriptions may be just around the corner for UK patients

Written by || 16th October 2018 || News analysis | Health and science | Regulation and legislation | GeographiesEurope United Kingdom

CBD products could be prescribed to British patients from as early as next month after the UK government announced plans to lift restrictions on the medical use of cannabis.

The change in policy follows recommendations from the Advisory Council on the Misuse of Drugs (ACMD) and the UK’s Chief Medical Adviser.

The new law will not limit the types of condition that can be considered for treatment with cannabis and cannabis-derivative products. Doctors will no longer need to seek approval from an expert panel in order for patients to access the medicines.

While CBD is not explicitly listed in the legislation, it is understood that it would fall under the umbrella of cannabis-derived medicines.

Read full article

Download the full news analysis

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

I'm already a subscriber
Author default picture

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Thanks for getting in touch with us

Please leave your enquiry and we will get back to you within 24 hours

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

Sign up to our newsletter

Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.